Digestive Diseases and Sciences

, Volume 53, Issue 8, pp 2195–2203 | Cite as

The COX-2 Selective Inhibitor-Independent COX-2 Effect on Colon Carcinoma Cells is Associated with the Delta1/Notch1 Pathway

Original Paper
First Online:
Received:
Accepted:

Abstract

Background Cyclooxygenase-2 (COX-2) is a key factor in the development of colorectal cancer, and non-steroidal anti-inflammatory drugs (NSAIDs) have anti-colorectal cancer activity. However, the potential molecular mechanism of the COX-2 selective inhibitor effect on proliferation and apoptosis of colon cancer cells is unclear. In this study, we have demonstrated for the first time that the Delta1/Notch1 signal transduction pathway mediates the COX-2 selective inhibitor effect on colorectal cancer cells, and we reveal the mechanism of the Notch1 pathway in terms of regulating the proliferation and apoptosis of colorectal cancer cells. Methods and Result Colon cancer cell lines HT-29 and SW480 were treated with NS-398 (a COX-2 selective inhibitor) and DAPT (a gamma-secretase inhibitor). The colormetric MTT cell proliferation assay and flow cytometry were used to measure cell proliferation and apoptosis. Reverse transcriptase (RT)-PCR and ELISA analyses were used to detect the levels of COX-2 mRNA expression and prostaglandin E2 (PGE2) concentration from the two cell lines, respectively. The expression of the Notch1, Delta1, ICN, Hes1 and NF-κB2 proteins was measured by Western blot. Immunohistochemistry results showed that Notch1 was expressed mainly in the cytoplasm and ICN mainly in the nucleus. COX-2 mRNA was highly expressed in HT-29 cells but not in SW480 cells. Both COX-2 mRNA expression and PGE2 concentration decreased in HT-29 cells treated with NS-398; however, PGE2 levels did not change in SW480 cells treated with NS-398. NS-398 and DAPT inhibited cell proliferation and induced apoptosis in a dose time-dependent manner accompanied by significantly decreased Notch1 activity (P < 0.01), and resulted in a significant down-regulation of Hes1 and NF-κB2 (P < 0.01). Conclusions Our results show that the selective COX-2 inhibitor may inhibit the proliferation and induce apoptosis in colon cancer cells through the COX-2-dependent pathway (HT-29) by decreasing the COX-2 mRNA/PGE2 levels and the activity of the COX-2-independent pathway (SW480). The Notch1 signal pathway mediates the effects of the COX-2 inhibitor on the proliferation and apoptosis of colon cancer cells. This may be a new target of the selective COX-2 inhibitor effect on colon cancer.

Keywords

Apoptosis Colon carcinoma Cyclooxygenase-2 inhibitor Notch signal transduction Proliferation 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This paper was supported by a grant from the National Nature Science Foundation of China (No. 30271269), the Key Program Foundation for Scientific Plan of Beijing (2005).

References

  1. 1.
    Timothy AC (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3:166–174CrossRefGoogle Scholar
  2. 2.
    Song X, Lin HP, Johnson AJ, et al. (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94:585–591PubMedGoogle Scholar
  3. 3.
    Ming L, Xiuyuan W, Xu XC (2001) Inhibition of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS-398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010–1016Google Scholar
  4. 4.
    Takahashi T, Ogawa Y, Kitaoka K, et al. (2005) Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide. Int J Mol Med 15:213–219PubMedGoogle Scholar
  5. 5.
    Gao J, Niwa K, Takemura M, et al (2005) Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 26:737–744PubMedGoogle Scholar
  6. 6.
    Wu J, Xia HH, Tu SP (2003) 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer peroxisome proliferator-activated receptors. Carcinogenesis 24:243–247PubMedCrossRefGoogle Scholar
  7. 7.
    Nakata H, Uemura Y, Kobayashi M, et al. (2003) Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. Cancer Sci 94:173–180PubMedCrossRefGoogle Scholar
  8. 8.
    Subhashini J, Mahipal SV, Reddanna P, et al. (2005) Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224:31–43PubMedGoogle Scholar
  9. 9.
    Zhang Z, Lai GH, Sirica AE, et al. (2004) Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39:1028–1037PubMedCrossRefGoogle Scholar
  10. 10.
    Artavanis-Tsakonas SR, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770–776PubMedCrossRefGoogle Scholar
  11. 11.
    Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev Biol 228:151–165PubMedCrossRefGoogle Scholar
  12. 12.
    Robbins J, Blondel BJ, Gallahan D, Callahan R (1992) Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J Virol 66:2594–2599PubMedGoogle Scholar
  13. 13.
    Gallahan D, Jhappan C, Robinson G, Hennighausen L, et al. (1996) Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 56:1775–1785PubMedGoogle Scholar
  14. 14.
    Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM (1997) Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 17:6265–6273PubMedGoogle Scholar
  15. 15.
    van Es JH, van Gijn ME, Riccio O, et al. (2005) Notch/g-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959–963PubMedCrossRefGoogle Scholar
  16. 16.
    Weijzen S, Rizzo P, Braid M, et al. (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Rastransformed cells. Nat Med 8:979–986PubMedCrossRefGoogle Scholar
  17. 17.
    Patel NS, Dobbie MS, Rochester M, et al. (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12:4836–4844PubMedCrossRefGoogle Scholar
  18. 18.
    Duan L, Yao J, Wu X, Fan M (2006) Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 98:479–490PubMedCrossRefGoogle Scholar
  19. 19.
    Wang Z, Zhang Y, Banerjee S, et al. (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106:2503–2513PubMedCrossRefGoogle Scholar
  20. 20.
    De Strooper B, Annaert W, Cuperset P, et. al. (1999) Presenilin-1-dependent g-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518–522Google Scholar
  21. 21.
    Kopan R, Goate A (2000) A common enzyme connects Notch signaling and Alzheimer’s disease. Genes Dev 14:2799–2806PubMedCrossRefGoogle Scholar
  22. 22.
    Wong GT, Manfra D, Poulet FM, et al. (2004) Chronic treatment with the g-secretase inhibitor LY-411, 575 inhibits b-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876–12882Google Scholar
  23. 23.
    Milano J, McKay J, Dagenais C, et al. (2004) Modulation of notch processing by g-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 1:341–358Google Scholar
  24. 24.
    Searfoss GH, Jordan WH, Calligaro DO, et al. (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional g-secretase inhibitor. J Biol Chem 278:46107–46116Google Scholar
  25. 25.
    Baron M (2003) An overview of the Notch signalling pathway. Semin Cell Dev Biol 14:113–119PubMedCrossRefGoogle Scholar
  26. 26.
    Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Nat Rev Cancer 6:347–359PubMedCrossRefGoogle Scholar
  27. 27.
    Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, et al. (2006) Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature 439:430–436PubMedCrossRefGoogle Scholar
  28. 28.
    Arumugam TV, Chan SL, et al. (2006) Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 12:621–623PubMedCrossRefGoogle Scholar
  29. 29.
    Kim SJ, Seo JH, Lee YJ, et al. (2005) Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. Oncology 68:204–211PubMedCrossRefGoogle Scholar
  30. 30.
    Heitzler P, Bourouis M, Ruel L, et al. (1996) Genes of the Enhancer of split and achaete-scute complexes are required for a regulatory loop between Notch and Delta during lateral signalling in Drosophila. Development 122:161–171PubMedGoogle Scholar
  31. 31.
    Oellers N, Dehiom M, Knustm E (1994) bHLH proteins encoded by the Enhancer of split complex of Drosophila negatively interfere with transcriptional activation mediated by proneural genes. Mol Gen Genet 244:465–473PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson AJ, Hsu AL, Lin HP (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366:831–837PubMedGoogle Scholar
  33. 33.
    Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313–323PubMedCrossRefGoogle Scholar
  34. 34.
    Mungamuri SK, Yang X, Thor AD, et al (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66: 4715–4724PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Hui Zhang
    • 1
  • Yingjiang Ye
    • 1
  • Zhigang Bai
    • 1
  • Shan Wang
    • 1
  1. 1.Surgical Oncology Laboratory and Department of Gastroenterological SurgeryPeking University People’s HospitalBeijingP.R. China

Personalised recommendations